Advanced Search

 

Study ID Status Title Patient Level Data
AA210010 Completed A randomised, double-blind, placebo-controlled, rising dose, 6-way crossover study to investigate the effect on heart rate of single doses of GW328267 (25 μg and 50 μg) and escalating cumulative doses of salbutamol (up to 1200 μg) administered alone and in combination to healthy male smokers. Study Listed on ClinicalStudyDataRequest.com
AA210012 Completed A randomised, double-blind, double dummy, placebo-controlled, three-way, balanced incomplete block, crossover study in patients with allergic rhinitis to compare the effect versus placebo of 7 days treatment with a new chemical entity (NCE) and 7 days treatment with intranasal fluticasone propionate 200 μg BID upon nasal clinical response after intranasal allergen challenge. Study Listed on ClinicalStudyDataRequest.com
AA210013 Completed A randomised, double-blind, placebo-controlled, crossover study to investigate the effects of pre-treatment with inhaled repeat doses of a new chemical entity (NCE) on the allergen induced late phase asthmatic response in mild asthmatic subjects. Study Listed on ClinicalStudyDataRequest.com
ABC107442 Completed A retrospective case-control study to estimate the sensitivity and specificity of a pharmacogenetic marker (HLA-B*5701) in subjects with and without hypersensitivity to abacavir.
AC2103473 Completed A randomised, double blind, placebo-controlled, double dummy, 4-way cross-over, dose ascending study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single inhaled doses of GSK233705 and tiotropium bromide (18µg) via DPI in COPD patients Study Listed on ClinicalStudyDataRequest.com
AC2105333 Completed A Randomised, Double-Blind, Placebo-Controlled, Dose Ascending, 3 Period Crossover Study To Examine The Safety, Tolerability, Pharmacodynamics And Pharmacokinetics Of Repeat Inhaled Doses Of GSK233705B In COPD Subjects. Study Listed on ClinicalStudyDataRequest.com
AC2106213 Completed A single-centre, open-label, sequential ascending cross over study to examine safety, tolerability, pharmacodynamics and pharmacokinetics of ascending single doses, nominally 10, 30, 70 and 110µg intravenous doses and a single 250µg oral dose of GSK233705 in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
AC2106956 Completed A multicentre, randomised, partially blinded, placebo-controlled, three-way crossover, incomplete block design study to investigate the safety, tolerability, pharmacodynamics/ efficacy and pharmacokinetics of dual bronchodilator therapy with salmeterol 50µg twice-daily plus two different doses of GSK233705B (20 and 50µg twice-daily), compared with placebo, salmeterol 50µg twice-daily alone, and Tiotropium 18µg once-daily alone, in subjects with chronic obstructive pulmonary disease Study Listed on ClinicalStudyDataRequest.com
AC2108378 Completed A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of twice-daily inhaled doses of GSK233705B formulated with the excipient Magnesium Stearate in COPD subjects for 7-days. Study Listed on ClinicalStudyDataRequest.com
AC2108380 Completed A single-centre, randomized, double-blind placebo-controlled, dose-ascending, cross-over study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705, formulated with the excipient magnesium stearate, in healthy volunteers Study Listed on ClinicalStudyDataRequest.com
AC2110664 Completed Dose-Ranging Study for GSK233705B Delivered Once Daily in Subjects with COPD Study Listed on ClinicalStudyDataRequest.com
AC4106889 Completed A single-centre, randomised, double-blind, placebo-controlled, dose-ascending, 3-cohort parallel-group study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GSK573719 administered as singledoses (750 μg and 1000 μg) and repeat doses over 14 days (250 μg–1000 μg once-daily) of GSK573719 in healthy male and female subjects. Study Listed on ClinicalStudyDataRequest.com
AC4108123 Completed A randomised, double blind, placebo-controlled, double dummy, 4-way cross-over, dose ascending study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK573719 (250, 500 and 1000 μg) and tiotropium bromide (18 μg) via DPI in COPD patients. Study Listed on ClinicalStudyDataRequest.com
AC5108696 Completed A randomized double-blind, placebo-controlled, crossover, dose escalation study to examine the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK1160724 and tiotropium bromide
ACE104325 Completed A randomized, open label comparative study to determine the proportion of asthma patients on SERETIDE Diskus 50/250 mcg b.i.d. achieving Total Control when given medication and compliance enhancement training compared to those receiving medication only.
ACT1840 Completed A multicentre pilot study of natural pentasaccharide (SR90107A /Org31540) for the prevention of deep venous thrombosis after total hip replacement.
ACT2445 Completed Pilot efficacy study of a single I.V. injection of Pentasaccharide (SR90107A/ORG 31540) in patients undergoing coronary angioplasty
ACT2545 Completed A multicentre dose finding study of once daily injection of Natural Pentasaccharide for the prevention of deep vein thrombosis after total hip replacement.
ADA103575 Completed A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID Study Listed on ClinicalStudyDataRequest.com
ADA103578 Completed A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID Study Listed on ClinicalStudyDataRequest.com
ADA109055 Completed A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects with Asthma Study Listed on ClinicalStudyDataRequest.com
ADA109057 Completed A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects with Asthma Study Listed on ClinicalStudyDataRequest.com
ADC105931 Terminated A Randomized, Double-Blind, Parallel-Group, 12-Week Study to Evaluate the Anti-Inflammatory Effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg BID Compared with Salmeterol DISKUS 50mcg Twice Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
ADC109043 Completed An evaluation of the prevalence of airway obstruction consistent with chronic obstructive pulmonary disease (COPD) in subjects with a history of cigarette smoking and symptoms of chronic bronchitis in a primary care setting
ADERE ADULT Completed A randomized, parallel group, open study to evaluate the impact of additional guidance provided by health care professionals on treatment compliance among asthmatic patients with persistent asthma (ADERE)

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.